Navigation Links
Oral osteoporosis meds appear to reduce the risk of jaw degradation

BOSTON, Mass. (Jan. 2, 2008) Athanasios Zavras began receiving messages from distraught patients in 2005 after case reports linked oral osteoporosis meds to bone death in the jaw. A number of doctors and dentists advised women and men taking these drugs to postpone dental work, fearing that procedures such as tooth extractions would exacerbate the problem. Thats when Zavras, an associate professor in the Harvard School of Dental Medicine, decided to take a closer look at the purported link.

After analyzing the medical claims of 714,217 people, Zavras, along with Vassiliki Cartsos at the Tufts University School of Dental Medicine and Shao Zhu of Ingenixi3 Drug Safety (the company that provided medical claims data), have concluded that oral osteoporosis meds seem to reduce the risk of jaw degradation. Clinical studies are needed to replicate and clarify the results, which appear in the January issue of the Journal of the American Dental Association.

This is good news for the roughly 3 million Americans who take Fosamax, Actonel, Boniva or similar osteoporosis meds orally, says Zavras, who is also director of dental public health in the Department of Oral Health Policy and Epidemiology.

The drugs, which are called bisphosphonates, inhibit cells that break down bone tissue, and a growing number of Americans with osteoporosis or low bone mass ingest them orally to halt bone loss. In fact, they have been used for this purpose since 1977. Some cancer patients also rely on bisphosphonates to prevent bone fragility and metastasis, but these individuals typically receive potent intravenous versions of the drugs.

In 2003, case reports linked the potent versions to bone death in the jaw, and subsequent studies confirmed the statistical significance of the association. Concern was limited to intravenous bisphosphonates until May 2005, when the Journal of Oral and Maxillofacial Surgery published a report on 63 patients with bone death in the jaw. Seven of those patients had taken oral bisphosphonates.

Zavras and his colleagues used a medical claims database from a large national health insurance plan to probe the connection. They analyzed records coded under osteoporosis, female breast cancer, lung cancer, prostate cancer or multiple myeloma from April 2000 through April 2006, which gave them a pool of 714,217 people.

Based on pharmacy and drug infusion claims, the researchers were able to determine if these individuals had received oral bisphosphonates, intravenous bisphosphonates, or neither. Next, the team examined claims for adverse bone outcomes and major surgery in the oral cavity to determine which patients might have experienced jaw death.

Osteoporosis patients who took oral bisphosphonates were slightly less likely to have adverse jaw outcomes than osteoporosis patients who were not taking the drugs. The protective association was statistically significant. A generally similar pattern emerged in the analysis of people with cancer. Those who had received oral bisphosphonates experienced protective associations or slightly increased risks that were not statistically significant. But receiving intravenous bisphosphonates significantly increased an individuals risk for adverse jaw outcomes in both cancer patients and those with osteoporosis.

Our findings on intravenous bisphosphonates are consistent with the literature, which makes me confident that our findings on oral bisphosphonates are correct, says Zavras. Were currently recruiting patients for a clinical study to confirm them.


Contact: Alyssa Kneller
Harvard Medical School

Related medicine news :

1. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
2. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
3. Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
4. Plenary lectures announced for worlds largest osteoporosis congress
5. Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis
6. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
7. Kaiser Permanente study shows electronic medical records and outreach improve osteoporosis care
8. Bad to the bone: UD research to shed light on osteoporosis
9. Geisinger rheumatologists redesign osteoporosis, rheumatoid arthritis care
10. Proposed Bill to Protect Patient Access to Osteoporosis Testing by Reversing Cuts in Medicare Reimbursement
11. High-trauma fractures in older men and women linked to osteoporosis
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
Breaking Medicine Technology: